The global glucosamine supplement market reached 2.1 billion dollars in 2024, with 15% annual growth and 23% of users aged 65 and older—the demographic most vulnerable to Alzheimer’s disease. Yet emerging research suggests this widespread use may carry hidden risks for those with existing neurodegeneration.
A new comprehensive study combining animal experiments with patient record analysis has identified a concerning pattern: glucosamine supplementation appears associated with accelerated cognitive decline specifically in individuals with Alzheimer’s disease. Paradoxically, the supplement showed neutral to protective effects in healthy brain tissue, suggesting disease-specific interactions previously unrecognized.
The research mechanism remains under investigation, though scientists point to altered glucose metabolism in diseased neural tissue as a potential explanation. These findings underscore the importance of supplement screening protocols tailored to disease states, particularly among elderly populations who often use multiple nutritional interventions simultaneously.
Read the full article on GMJ Newsroom.
Was this article helpful?
